Lowest Price Guaranteed
Pages
593
Last Updated
April 2026
View Count
24898
The global autoinjectors market is estimated to grow from USD 170 billion in 2025 to reach USD 181 billion in 2026 and USD 299 billion by 2035, representing a higher CAGR of 5.7% during the forecast period.
To learn more about this report, request a free sample copy
Autoinjectors are self-injection devices that deliver a specific dose of a drug / therapeutic substance with simple push of a button. Autoinjectors are spring-loaded syringes which work on injection mechanism and include pre-measured medication, which eliminates the need to draw medication from a separate vial, thus resolving various injection-related compliance issues faced by the patients.
Owing to the inadequacies of the conventional drug delivery systems, autoinjectors have steadily gained prominence, especially in the immediate treatment of emergency situations, such as anaphylactic shocks, strokes and rheumatoid arthritis.
EpiPen has been the poster child for autoinjectors. Several blockbuster biologics are also approved in autoinjector formats such as Humira Pen and Rebif Rebidose. Key biosimilar developers have also launched their products in autoinjectors. Cyltezo (adalimumab biosimilar) from Boehringer Ingelheim and Udenyca (pegfilgrastim biosimilar) from Coherus Biosciences are some approved biosimilars available in autoinjectors.
Several original equipment manufacturers (OEMs) active in this market include SHL Medical (Switzerland), Owen Mumford (UK), Ypsomed (Switzerland), Elcam Medical (Israel), Union Medico (Denmark), Aptar Pharma (US) and Gerresheimer (Germany) to name a few. These autoinjector manufacturers are continuously expanding their product capacities to meet the growing demand.
| Key Report Attributes | Details | |
| Historical Trend | Since 2024 | |
| Forecast Period | Till 2035 | |
| Market Size 2026 | $ 181 Billion | |
| Market Size 2035 | $ 299 Billion | |
| CAGR (Till 2035) | 5.7% | |
The global autoinjectors market analysis also features the likely distribution of the current and forecasted opportunity within the autoinjectors domain across various segments, such as usability, route of administration, type of molecule delivered, type of actuation mechanism, volume of container, end user, target indication and geographical regions.
We have created three market forecast scenarios, conservative, base and optimistic, to account for future uncertainties in parameters and enhance the robustness of our model. These scenarios represent different tracks of the industry's evolution.
The growth in the autoinjectors market size over the next decade is driven largely by the shift toward home-based healthcare, coupled with the loss of exclusivity of biologics patents, which creates opportunities for patent life extension through integration with autoinjectors.
Several recent developments have taken place in the field of autoinjectors, and we outline some of these below. These developments, even if they arose after our market report’s release, support the overall global autoinjectors market trends detailed in our analysis.
The market research report presents an in-depth analysis of the various autoinjector manufacturers and drug-device combination developers, across different segments, as defined in the table below:
| Market Segmentations | Details | |
| Usability |
|
|
| Route of Administration |
|
|
| Type of Molecule Delivered |
|
|
| Type of Actuation Mechanism |
|
|
| Volume of Container |
|
|
| End User |
|
|
| Target Indication |
|
|
| Geographical Regions |
|
|
With the growing adoption of self-administration devices and ongoing advancements in technologies the market for autoinjectors is likely to grow, in the foreseen future.
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:
Autoinjectors domain will mark a turning point in 2026. Autoinjectors manufacturers are actively engaged in developing technologically advanced autoinjectors. In this context, Amir Genosar, (Chief Executive Officer, Aktivax) shared about their PenPal autoinjector platform stating that, “This technology platform allows pharmaceutical partners to use different sized primary containers, and any needle gauge and length, without making any significant changes to the actual autoinjector device.”
 |
 |
| Report Deliverables | Details | |
| Analytical Insights Covered |
|
|
| Global Autoinjectors Companies Profiled |
(Full list of 120+ companies captured is available in the report) | |
| PowerPoint Presentation (Complementary) |
Available | |
| Customization Scope | 15% Free Customization | |
The “Autoinjectors Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the market landscape, market size and future opportunities within the autoinjectors industry, during the given forecast period.
The autoinjectors market features over 145 autoinjectors. Majority (85%) of the autoinjectors are commercialized while 15% are under development. Further, over 60% of the autoinjectors are disposable. Notably, around 80% of the autoinjectors have a fully automatic needle actuation mechanism, followed by those having manual actuation mechanism (21%).
In addition, market landscape features more than 50 autoinjector manufacturers across the globe which includes very large, large, mid-sized and small players. Notably, over 40% of the companies in autoinjectors industry are based in North America, followed by Europe (39%).
 |
During our research, we came across more than 155 marketed autoinjector drug combination products. More than 70% of the approved combination products employ syringes for drug storage while 32% of the devices have cartridges as the primary drug container.
It is worth highlighting that, in May 2025, Amneal Pharmaceuticals, received U.S. FDA approval for Brekiya, the first autoinjector delivering dihydroergotamine mesylate for treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.
The global autoinjectors market size is likely to be worth USD 181 billion in 2026. The rise in incidence of chronic diseases, growing need for novel biologics and biosimilars, and rising demand for self-injection devices are the primary drivers for the growth of this market.
The autoinjector market is likely to grow at a CAGR of 5.7% during the forecast period. In terms of usability, the disposable autoinjectors market is likely to capture the major market share during the forecast period.
In recent years, industry stakeholders have inked several partnerships, in order to consolidate their presence in this field. Interestingly, most of the agreements (21%) were acquisitions, followed by product co-development agreements (14%). In this context, in January 2025, Aktiv Medical entered into a partnership with a global pharma company, to co-develop a high-concentration, large-dose volume injection drug using its PenPal autoinjector device platform.
In the past four years, players have filed / granted over 1,100 patents focused on autoinjectors, indicating the substantial efforts made by researchers engaged in this domain. Most of the filed patents include technological advancements in autoinjectors, focusing on improving patient safety and eliminating dosing errors. It is worth highlighting that most of the patents (52%) in this domain were patent applications, followed by granted patents (40%).
 |
Recent advancements in the connected drug delivery devices technology involve the integration of modern features in the devices, including bluetooth connectivity, smart dosing and needleless drug administration in the connected auto-injector devices for effective drug delivery.
For instance, Owen Mumford’s UniSafe® reusable autoinjector is a connected auto-injector, which uses a 1 mL UniSafe® safety syringe, the only disposable component, for drug delivery. Another notable example is Eli Lilly manufactured REZVOGLAR™ KwikPen® autoinjector, a cartridge-based autoinjector manufactured by Eli Lilly and Company.
North American companies will likely dominate the global autoinjectors industry in 2035, with 55% of players based in the region enhancing their offerings. North America features the presence of the majority of autoinjector manufacturers, followed by Europe.
The market in Asia-Pacific is likely to grow at a relatively higher CAGR, during the forecast period till 2035 during the forecast period. Growth in this region will be driven by a rise in chronic conditions like diabetes and rheumatoid arthritis, supported by an increase in diagnosis and treatment rates.
Over the years, the healthcare burden has increased significantly due to the growing prevalence of chronic diseases, including asthma, diabetes, multiple sclerosis and rheumatoid arthritis. In this context, according to NCOA research, nearly 95% of adults suffer from at least one chronic illness. Further, the reluctance of individuals to receive injections in a clinical setting due to privacy concerns and discomfort is another challenge for healthcare providers. As such, the patients prefer self-administration of drugs for chronic conditions.
The development and commercialization of biosimilars is also driving the demand for autoinjectors. In a recent instance, Sandoz launched Pyzchiva (Ustekinumab biosimilar) autoinjector in Europe in May 2025. Another biosimilar developer, Celltrion received positive Committee for Medicinal Products for Human Use (CHMP) opinion for autoinjector formulation of Omlyclo (omalizumab biosimilar) in March 2025. As several innovator biologics stand to lose their patent protection, biosimilar developers are finding opportunity to innovate with the development of autoinjector-biosimilar combinations.
The growing need for self-administration of medicines and personalized therapies, coupled with the advancements in technology, and rising prevalence of chronic disease is contributing significantly to the increased demand for autoinjectors. Autoinjectors have demonstrated their ability to support convenient and safe medication delivery for the effective treatment of a myriad of disease indications.
Lead Author: Ankita Rana
Lead Reviewer: Parneet Kaur
Chief Editor: Prachi Bhalla